BioTuesdays Feature Articles | Life Sciences News

Feature

Imagin Medical taking bladder cancer imaging to next level

By Len Zehrs Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically...

June 19, 2018

Feature

XOR Labs pioneering technology to expand lung transplantation

By Len Zehrs Closely-held XOR Labs hopes to dramatically increase the number of lungs suitable for transplantation with its Ex-Vivo Lung Perfusion (EVLP) technology. “Only about 20 out of every 100 donated lungs are...

June 12, 2018

Feature

NanoSphere spearheads delivery of medical nano-encapsulated THC/CBD

By Len Zehrs NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has developed a newly-patented delivery technology that increases the bioavailability and bioactivity of its Evolve line of gel-like cannabinoids for the...

June 5, 2018

Feature

Gecko Biomedical readies rapid acceleration of polymer platform

By Melane Sampson Since developing and validating SETALUM, a versatile vascular sealant in 2013, closely-held, Paris-based Gecko Biomedical is now poised to seek FDA approval for SETALUM, validate new programs, and open...

May 29, 2018

Feature

Nanobiotix pioneering nanomedicine in new paradigm against cancer

By Len Zehrs France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients. “What differentiates us is that we...

May 15, 2018

Feature

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

By Len Zehrs In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its...

May 8, 2018

Feature

Aimmune readies filing for FDA approval of peanut allergy treatment

By Len Zehrs On the heels of positive data from its PALISADE pivotal trial, Aimmune Therapeutics (NASDAQ:AIMT) plans to submit a biologics license application with the FDA by the end of 2018 for its peanut allergy...

May 1, 2018

Feature

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

By Len Zehrs During the past four years, closely-held Cyclica has developed and validated a patented structure-based and AI-augmented proteome-screening platform, known as Ligand Express. “The platform enables critical...

April 24, 2018

Feature

Moberg Pharma parlaying topical niche brands to fuel innovation engine

By Len Zehrs Sweden’s Moberg Pharma (OMX:MOB) is focused on maximizing the potential of its market leading position in over-the-counter sales of topical dermatology products to drive development of new therapies for the...

April 17, 2018

Feature

Tear Film Innovations readies launch of iLux device for dry eye disease

By Len Zehrs Closely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease. The...

April 10, 2018

Feature

Myomo scaling up distribution of MyoPro robotic arm brace

By Len Zehrs Myomo (NYSE American:MYO) is moving from a controlled introduction over the past few years to a scale up sales and distribution of its MyoPro product line of lightweight, non-invasive, powered arm braces to...

April 3, 2018

Feature

Australia tax incentives spurring R&D

By Len Zehrs Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials. The incentives provide businesses...

March 27, 2018

Feature

Vital Therapies pivotal ELAD trial to read out at end of third quarter

By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...

March 20, 2018

Feature

DarioHealth simplifies diabetes with managed care platform

By Len Zehrs DarioHealth’s (NASDAQ:DRIO) diabetes managed care platform covers all facets of the disease, with a blood glucose device coupled directly to a patient’s smartphone to provide 100% data...

March 13, 2018

Feature

liberDi readies first-in-man study of portable dialysis system

By Len Zehrs Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed...

March 6, 2018

Feature

Scientus Pharma considering go-public transaction on heels of financing

By Len Zehrs Closely-held Scientus Pharma hopes to go public in mid-year, possibly through a reverse takeover of a publicly traded shell company, following a successful $15.8-million private equity financing, which...

February 27, 2018

Feature

3DS Telo-HL test aims to personalize cancer treatment

By Len Zehrs 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) has reported positive results from a preliminary analysis of trial data for Telo-HL, its test for Hodgkin’s lymphoma (HL) that is designed to personalize...

February 20, 2018

Feature

Strong scientific rationale for IntelGenx montelukast program

By Len Zehrs IntelGenx (OTCQX:IGXT; TSXV:IGX), which has initiated a proof-of-concept study with its Montelukast VersaFilm in patients with Alzheimer’s disease, using a drug originally approved in 1997 for the...

February 13, 2018

Feature

Eiger BioPharma has multiple catalysts in orphan diseases in 2018

By Len Zehrs Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a...

February 6, 2018

Feature

Spartan Bioscience takes aim at Legionnaires’ disease

By Len Zehrs Closely-held Spartan Bioscience’s recently launched an on-site rapid DNA test for Legionnaires’ disease that has the potential to eliminate lengthy culture testing in third-party labs and detect the...

January 30, 2018

Feature

FDA advisory vote on TLANDO not a knockout for Lipocine

By Len Zehrs Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is...

January 23, 2018

Feature

Chi-Med transforming into fully integrated pharma

By Len Zehrs After 17 years of blistering growth in China, Hutchison China Meditech (Chi-Med) (AIM, NASDAQ:HCM) is taking center stage as a global drug innovator, with a fully integrated pipeline approaching regulatory...

January 9, 2018

Imagin Medical taking bladder cancer imaging to next level

XOR Labs pioneering technology to expand lung transplantation

NanoSphere spearheads delivery of medical nano-encapsulated THC/CBD

Gecko Biomedical readies rapid acceleration of polymer platform

Nanobiotix pioneering nanomedicine in new paradigm against cancer

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

Aimmune readies filing for FDA approval of peanut allergy treatment

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

Moberg Pharma parlaying topical niche brands to fuel innovation engine

Tear Film Innovations readies launch of iLux device for dry eye disease

Myomo scaling up distribution of MyoPro robotic arm brace

Australia tax incentives spurring R&D

Vital Therapies pivotal ELAD trial to read out at end of third quarter

DarioHealth simplifies diabetes with managed care platform

liberDi readies first-in-man study of portable dialysis system

Scientus Pharma considering go-public transaction on heels of financing

3DS Telo-HL test aims to personalize cancer treatment

Strong scientific rationale for IntelGenx montelukast program

Eiger BioPharma has multiple catalysts in orphan diseases in 2018

Spartan Bioscience takes aim at Legionnaires’ disease

FDA advisory vote on TLANDO not a knockout for Lipocine

Chi-Med transforming into fully integrated pharma

General

More